AbbVie reports positive results for RINVOQ in SELECT-CHOICE phase 3 trial

AbbVie said that RINVOQ (upadacitinib, 15 mg, once daily) has met the primary endpoint and key secondary endpoints in the SELECT-CHOICE phase 3 trial in ... Read More